Testing for MODY: From Blood Work to Genetics
At a Glance
Diagnosing MODY is a multi-step process that starts with ruling out Type 1 diabetes using autoantibody tests and measuring insulin production with a C-peptide test. If blood tests and clinical risk scores suggest MODY, a genetic sequencing panel is used to confirm the exact mutation.
Getting a definitive MODY diagnosis is a step-by-step process. Because MODY can look so much like Type 1 or Type 2 diabetes, doctors use a series of “filters” to narrow down the possibilities. This journey usually moves from simple blood tests to clinical risk assessments, and finally, to the gold standard: genetic sequencing [1][2].
Step 1: Ruling Out Autoimmunity
The first step is often to check if your diabetes is caused by an immune system attack, which would indicate Type 1 diabetes (T1D).
- Diabetes Autoantibodies: These are proteins (like GADA, IA-2A, and ZnT8A) that the body produced if it is attacking its own insulin-producing cells [1][3].
- The MODY Connection: Because MODY is caused by a genetic mutation and not an immune problem, these antibody tests are typically negative in people with MODY [1][4]. If you test positive for these antibodies, it strongly suggests Type 1 diabetes instead [3].
Step 2: Measuring Insulin Production
If your antibodies are negative, the next question is: Is your body still making its own insulin?
- C-Peptide Test: When the pancreas makes insulin, it releases a byproduct called C-peptide in equal amounts [1][5]. Measuring C-peptide tells doctors how much “homegrown” insulin you are still producing.
- Why it Matters: In Type 1 diabetes, C-peptide levels usually drop to nearly zero within a few years of diagnosis [6][7]. In contrast, people with MODY often continue to produce measurable levels of C-peptide even decades after their diagnosis [8][9].
- Timing: This test is most definitively helpful for distinguishing MODY from Type 1 diabetes 3 to 5 years after diagnosis. Newly diagnosed Type 1 patients can still have detectable C-peptide during their “honeymoon phase,” but persistent C-peptide long after diagnosis is a major “red flag” for MODY [10][11].
Step 3: Calculating Your Risk
Before ordering genetic tests, many specialists use a MODY Probability Calculator (such as the Exeter model) [12][2]. This tool combines several pieces of your medical history to give a percentage risk score, including:
- Age at diagnosis: MODY usually appears before age 25 [13].
- Body Mass Index (BMI): MODY patients are often (though not always) at a healthy weight, whereas Type 2 is frequently associated with a higher BMI [2].
- Current Treatment: If you are on insulin but produce your own C-peptide, or if your blood sugar is very sensitive to oral pills, your score goes up [14][15].
Step 4: The Gold Standard (Genetic Testing)
If your risk score is high, the final step is Molecular Genetic Testing [16]. Modern labs use Next-Generation Sequencing (NGS) panels, which can scan many different MODY genes at the same time [17][13].
- The Panel: Instead of testing one gene at a time, an NGS panel looks at a group of genes simultaneously. This is faster and more accurate for finding rare mutations [18][19].
- The Result: A “pathogenic” or “likely pathogenic” result confirms the diagnosis and identifies your specific subtype [20]. This allows your doctor to practice precision medicine [14].
Advocating for Yourself
Genetic testing can sometimes be expensive or difficult to access due to insurance denials [21]. If you meet the clinical criteria, self-advocacy is key:
- Ask your doctor to run your data through the Exeter MODY Probability Calculator and document the score in your chart to justify testing [12].
- Ensure your doctor uses the correct diagnostic codes for suspected monogenic diabetes, not just general Type 1 or Type 2 codes.
- Ask about financial assistance programs. Many specialized genetic testing laboratories offer sliding-scale payment options or patient assistance programs.
| Test | What it measures | MODY Result |
|---|---|---|
| Autoantibodies | Immune system attack | Negative [1] |
| C-Peptide | Natural insulin production | Positive/Detectable [10] |
| Genetic Panel | DNA mutations | Mutation Found [16] |
Previous: The Genetics of MODY | Return to Home | Next: Treating MODY
Common questions in this guide
How do doctors tell the difference between MODY and Type 1 diabetes?
What does a C-peptide test show for MODY?
What is the Exeter MODY Probability Calculator?
How is a MODY diagnosis officially confirmed?
One line in your results can change your plan.
If the MODY probability score is high, molecular genetic testing is the final step. We check your results against the latest research to help you prepare for what’s next.
Related questions
Get notified when new evidence is published on MODY.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study.
Carlsson A, Shepherd M, Ellard S, et al.
Diabetes care 2020; (43(1)):82-89 doi:10.2337/dc19-0747.
PMID: 31704690 - 2
Maturity-Onset Diabetes of the Young (MODY): Making the Right Diagnosis to Optimize Treatment.
Amed S, Oram R
Canadian journal of diabetes 2016; (40(5)):449-454 doi:10.1016/j.jcjd.2016.03.002.
PMID: 27130141 - 3
Autoantibodies against ZnT8 are rare in Central-European LADA patients and absent in MODY patients, including those positive for other autoantibodies.
Heneberg P, Šimčíková D, Čecháková M, et al.
Journal of diabetes and its complications 2019; (33(1)):46-52 doi:10.1016/j.jdiacomp.2018.10.004.
PMID: 30377089 - 4
The unique clinical spectrum of maturity onset diabetes of the young type 3.
Lebenthal Y, Fisch Shvalb N, Gozlan Y, et al.
Diabetes research and clinical practice 2018; (135()):18-22 doi:10.1016/j.diabres.2017.10.024.
PMID: 29107759 - 5
Clinical heterogeneity of type 1 diabetes (T1D) found in Asia.
Park Y, Wintergerst KA, Zhou Z
Diabetes/metabolism research and reviews 2017; (33(7)) doi:10.1002/dmrr.2907.
PMID: 28544229 - 6
HLA-guided identification of monogenic diabetes in antibody-negative type 1 diabetes: frequency and characteristics.
Chen Y, Yin M, Xie Y, et al.
Diabetes & metabolism 2026; (52(2)):101741 doi:10.1016/j.diabet.2026.101741.
PMID: 41679598 - 7
Investigating misclassification of type 1 diabetes in a population-based cohort of British Pakistanis and Bangladeshis using polygenic risk scores.
Liu T, Sankareswaran A, Paterson G, et al.
Scientific reports 2025; (15(1)):1168 doi:10.1038/s41598-024-80348-8.
PMID: 39805939 - 8
PDX-1 related diabetes: a case series of two families highlighting challenges in MODY diagnosis.
da Silva BT, Pinheiro AT, Saraiva M, et al.
Acta diabetologica 2026; (63(2)):201-208 doi:10.1007/s00592-025-02614-z.
PMID: 41201616 - 9
Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood.
Bacon S, Kyithar MP, Condron EM, et al.
Acta diabetologica 2016; (53(6)):965-972 doi:10.1007/s00592-016-0890-9.
PMID: 27552834 - 10
Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes.
Patel KA, Weedon MN, Shields BM, et al.
Diabetes care 2019; (42(2)):e16-e17 doi:10.2337/dc18-0373.
PMID: 30409810 - 11
C-peptide and residual β-cell function in pediatric diabetes - state of the art.
Jamiołkowska-Sztabkowska M, Głowińska-Olszewska B, Bossowski A
Pediatric endocrinology, diabetes, and metabolism 2021; (27(2)):123-133 doi:10.5114/pedm.2021.107165.
PMID: 34514768 - 12
A Clinical Prediction Model to Distinguish Maturity-Onset Diabetes of the Young From Type 1 and Type 2 Diabetes in the Chinese Population.
Fu J, Ping F, Wang T, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021; (27(8)):776-782 doi:10.1016/j.eprac.2021.05.002.
PMID: 33991656 - 13
How Recent Advances in Genomics Improve Precision Diagnosis and Personalized Care of Maturity-Onset Diabetes of the Young.
Vaxillaire M, Froguel P, Bonnefond A
Current diabetes reports 2019; (19(9)):79 doi:10.1007/s11892-019-1202-x.
PMID: 31385057 - 14
Clinical and genetic characterization and long-term evaluation of individuals with maturity-onset diabetes of the young (MODY): The journey towards appropriate treatment.
Campos Franco P, Santos de Santana L, Dantas Costa-Riquetto A, et al.
Diabetes research and clinical practice 2022; (187()):109875 doi:10.1016/j.diabres.2022.109875.
PMID: 35472491 - 15
GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated.
Carmody D, Naylor RN, Bell CD, et al.
Acta diabetologica 2016; (53(5)):703-8 doi:10.1007/s00592-016-0859-8.
PMID: 27106716 - 16
A rare case of congenital hyperinsulinism (CHI) due to dual genetic aetiology involving HNF4A and ABCC8.
Apperley L, Giri D, Houghton JAL, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2019; (32(3)):301-304 doi:10.1515/jpem-2018-0389.
PMID: 30730840 - 17
Targeted next generation sequencing in patients with maturity-onset diabetes of the young (MODY).
Özdemir TR, Kırbıyık Ö, Dündar BN, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(12)):1295-1304.
PMID: 30447144 - 18
NGS Analysis Revealed Digenic Heterozygous GCK and HNF1A Variants in a Child with Mild Hyperglycemia: A Case Report.
Iafusco F, Maione G, Mazzaccara C, et al.
Diagnostics (Basel, Switzerland) 2021; (11(7)) doi:10.3390/diagnostics11071164.
PMID: 34202200 - 19
Case Report: Identification of a HNF1A exons 1-10 heterozygous deletion in a Chinese MODY family.
Lei M, Xue M, Wang H, et al.
Frontiers in endocrinology 2026; (17()):1743021 doi:10.3389/fendo.2026.1743021.
PMID: 41778156 - 20
Novel insights into genetics and clinics of the HNF1A-MODY.
Valkovicova T, Skopkova M, Stanik J, Gasperikova D
Endocrine regulations 2019; (53(2)):110-134.
PMID: 31517624 - 21
Two novel GCK mutations in Chinese patients with maturity-onset diabetes of the young.
Wang T, Zhu M, Wang Y, et al.
Endocrine 2024; (83(1)):92-98 doi:10.1007/s12020-023-03509-1.
PMID: 37847371
This page explains the diagnostic tests for MODY for educational purposes. Always consult your endocrinologist or a genetic counselor to interpret your lab results and determine the right testing strategy for you.